28th Sep 2016 07:00
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Appointment of Broker
OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces that it has appointed finnCap as its sole broker with immediate effect.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information:
OptiBiotix Health plc | www.optibiotix.com | ||
Stephen O'Hara, Chief Executive | Contact via Walbrook below | ||
Cairn Financial Advisers LLP (Nominated Adviser) | Tel: 020 7148 7900 | ||
Liam Murray / Jo Turner | |||
finnCap (Sole Broker) | |||
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance) | Tel: 020 7220 0500 | ||
Tony Quirke (Corporate Broking) | |||
Walbrook PR Ltd | Tel: 020 7933 8780 or [email protected] | ||
Anna Dunphy | Mob: 07876 741 001 | ||
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
Related Shares:
OptiBiotix Health